Clene to Present at Upcoming Investor Conferences
Clene schedules in-person and virtual investor conference appearances with webcast access for its late September 2026 presentation.
Rhea-AI Summary
Clene (CLNN) will participate in two investor conferences on September 29–30, 2026, offering presentations and 1x1 investor meetings.
Management will attend the 5th Annual ROTH Healthcare Opportunities Conference in New York on September 29, where meetings are arranged via ROTH representatives. Clene will also present at the Lytham Partners Investor Conference Fall Event, held virtually September 29–30, with a presentation at 9:45 a.m. ET and additional 1x1 meetings scheduled through Lytham representatives. A webcast of the Lytham presentation will be accessible through the Events section of Clene’s website or via the provided webcast links.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences.
5th Annual ROTH Healthcare Opportunities Conference
Date: September 29, 2026
Location: New York, NY
Format: 1x1 meetings
1x1 Meetings: Please contact your ROTH representative
Lytham Partners Investor Conference Fall Event
Date: September 29-30, 2026
Time of Presentation: 9:45 am ET
Location: Virtual
Format: Presentation and 1x1 meetings
1x1 Meetings: Please contact your Lytham representative
Webcast: link to webcast
A webcast of the presentation will be available on the “Events” section of the Clene website or using the webcast links above.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
Media Contact: Caroline Wagner, FTP; CWagner@ftpadvocacy.com; (267) 294-6563
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How can investors schedule 1x1 meetings with Clene at these conferences?
For the 5th Annual ROTH Healthcare Opportunities Conference, investors are instructed to contact their ROTH representative to arrange 1x1 meetings. For the Lytham Partners Investor Conference Fall Event, investors should contact their Lytham representative to schedule 1x1 meetings.
How can investors access Clene’s webcast at the Lytham Partners Investor Conference?
A webcast of Clene’s presentation at the Lytham Partners Investor Conference Fall Event will be available in the “Events” section of the Clene website or through the webcast links referenced for the event.
When and where will Clene’s conferences take place?
The 5th Annual ROTH Healthcare Opportunities Conference will take place on September 29, 2026, in New York, NY. The Lytham Partners Investor Conference Fall Event will be held virtually from September 29–30, 2026, with Clene’s presentation scheduled for 9:45 a.m. ET.